Viridian Therapeutics, Inc.\DE (VRDN) EBT Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly EBT Margin of 79261.7% for Q1 2026, up 5151746.0% year-over-year from N/an in Q1 2025, and down 5.35% quarter-over-quarter from 75234.09% in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) EBT Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's EBT Margin history runs 14 years deep, the most recent figure standing at 79261.7% for Q1 2026.
- In Q1 2026, EBT Margin rose 5151746.0% year-over-year to 79261.7%; the TTM figure through Mar 2026 stood at 504.51% (up 11131735.0% YoY), while the FY2025 annual figure was 921.42%, up 15667758.0% from the prior year.
- EBT Margin for Q1 2026 stood at 79261.7%, down from 75234.09% in the prior quarter.
- The five-year high for EBT Margin was 49.67% in Q3 2025, with the low at 148888.0% in Q2 2025.
- The 5-year median for EBT Margin is 76476.39% (2023), against an average of 72374.11%.
- The sharpest annual moves came in 2023 and 2025: EBT Margin tumbled 7347718 bps in 2023, then surged 10633289 bps in 2025.
- Viridian Therapeutics, Inc.\DE's EBT Margin stood at 43438.1% in 2022, then tumbled by 169 bps to 116915.28% in 2023, then climbed by 6 bps to 109850.0% in 2024, then jumped by 32 bps to 75234.09% in 2025, then fell by 5 bps to 79261.7% in 2026.
- Business Quant data shows VRDN's EBT Margin at 79261.7% in Q1 2026, 75234.09% in Q4 2025, and 49.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -56,619.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56,619.37% |
| Mar 31, 2026 | -79,261.70% |
| Dec 31, 2025 | -75,234.09% |
| Sep 30, 2025 | -49.67% |
| Jun 30, 2025 | -148,888.00% |
| Mar 31, 2025 | -130,779.17% |
| Dec 31, 2024 | -109,850.00% |
| Sep 30, 2024 | -106,382.56% |
| Jun 30, 2024 | -101,333.33% |
| Mar 31, 2024 | -80,125.00% |
| Dec 31, 2023 | -116,915.28% |
| Sep 30, 2023 | -66,194.44% |
| Jun 30, 2023 | -76,476.39% |
| Mar 31, 2023 | -69,577.55% |
| Dec 31, 2022 | -43,438.10% |
| Sep 30, 2022 | -2,421.84% |
| Jun 30, 2022 | -11,537.89% |
| Mar 31, 2022 | -11,894.91% |
| Dec 31, 2021 | -13,618.22% |
| Sep 30, 2021 | -6,751.44% |